Comparison of HPLC and turbidimetric immuno-inhibition method for determination of HbA1c

Abstract

Purpose: Measurement of HbA1c is widely accepted as retrospective index of glycemic control in Diabetes Mellitus (DM) patients. Currently several different methods are used in clinical laboratories for measurement of HbA1c. However most of these methods are complicated and expensive. In the present study we aimed to make a comparison between HPLC and turbidimetric immuno-inhibition methods for determination HbA1c to decide the more suitable one for clinical laboratories. Methods: One hundred and seventy eight patients with DM were included into the study. Blood levels of HbA1cwere determined by both HPLC and turbidimetric immuno-inhibition methods. Data obtained from two methods were compared with various statistical techniques. Results: There was no significant diffe rence between HbA1c results measured with HPLC (%6.27±2.0) and turbidimetric immuno-inhibition (%6.31±2.2) methods (p>0.05). We also observed a strong positive corelation between both methods (r = 0.934, p < 0.001). Conclusion: In clinical laboratory practice HPLC method is complicated, time consuming and expensive. However turbidimetric immuno-inhibition method is simple, chip and could be apply to most autoanalyzers which is common in clinical laboratories. We concluded that turbidimetric immuno-inhibition method should be preferred to HPLC method for measurement of HbA1c for monitoring glycemic control in Diabetes Mellitus patients

Keywords

• Diabetes mellitus,HbA1c,high performance liquid chromatography,turbidimetric immunoinhibition

HbA1c Ölçümünde HPLC ve Türbidimetrik Immüno-inhibisyon Yöntemlerinin Karsilastirilmasi

Abstract

Amaç: Diabetes Mellitus (DM) hastalarinda retrospektif glisemik kontrolün degerlendirilmesinde HbA1c ölçümü yaygin olarak kullanilmaktadir. Günümüzde klinik laboratuarlarda HBA1c ölçümü için çok sayida farkli yöntemler kullanilmaktadir. Bunlarin bir kismi karmasik ve pahali yöntemlerdir. Bu çalismada HbA1cölçümünde kullanilan Yüksek performansli sivi kromatografi-High performance liquid chromatography (HPLC) ve türbidimetrik immüno-inhibisyon yöntemlerini karsilastirilarak klinik laboratuarlar için daha uygun olanini seçmeyi amaçladik. Gereç ve Yöntem: Çalismaya DM’li 178 olgu alindi. Olgulardan alinan kan örneklerinden HbA1c düzeyleri hem HPLC ve hem de türbidimetrik immüno-inhibisyon yöntemleriyle çalisildi. Her iki yöntemle elde edilen veriler farkli istatistiksel teknikler kullanilarak karsilastirildi. Bulgular: HPLC (%6.27±2.0) ve türbidimetrik immüno-inhibisyon (%6.31±2.2) yöntemleriyle ölçülen HbA1cdüzeyleri arasinda anlamli bir fark bulunamadi (p>0.05). Yapilan korelasyon analizinde iki yöntemin sonuçlari arasinda pozitif ve güçlü bir korelasyon oldugu görüldü (r = 0.934, p < 0.001). Sonuç: Klinik laboratuarlarda kullanilan HPLC yöntemi karmasik, zaman alici ve pahali bir yöntemdir. Buna karsilik türbidimetrik immüno-inhibis yon yöntemi basit, ucuz ve laboratuarlarda yaygin olarak bulunan çok sayida otoanalizörlere uyarlanabilir. Bu nedenle DM’li hastalarin glisemik kontrol ve takiplerinde HbA1c ölçümü için türbidimetrik immüno-inhibisyon yöteminin HPLC’ye tercih edilmesi gerektigini düsünmekteyiz

Keywords

• Diabetes Mellitus,HbA1c,yüksek performansli sivi kromatografisi,türbidimetrik immünoinhibisyon

References

1. World Health Organization. Welcome to the Diabetes programme. http://www.who.int/diabetes/en/
2. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent Diabetes Mellitus. N Eng J Med. 329:977-986, 1993.
3. Goldstein DE, Little RR, Wiedmeyer HM, England JD, Rohlfing CL, Wilke AL: Is glycohemoglobin testing useful in diabetes mellitus? Lessons from the diabetes control and complications trial. Clin Chem. 40:1637– 1640,1994.
4. Sacks DB, Path FRC. Carbohydrates. In: Burtis CA, Ashwood ER, Bruns DE, Editors. Tietz Textbook of Clinical Chemistry and Molecular Diagnostics. Missouri: Elsevier Saunders Inc. 837-901, 2006.
5. Kurt I: Glikozile hemoglobin (HbA1c) ölçümü vediabetes mellitusun uzun dönem glisemik kontrolünde kullanilmasi. Gülhane Tip Dergisi. 45:387-395, 2003.
6. Gomes MB, Piccirillo LJ, Nogueira VG, Matos HJ: Acute-phase proteins among patients with type 1 diabetes. Diabetes Metab. 29:405–411, 2003.
7. Gillery P, Labbé D, Dumont G, Vassault A: Glycohemoglobin assays evaluated in a large- scale quality control survey. Clin Chem. 41:1644– 1648, 1995.
8. Eckfeldt JH, Bruns DE: Another step toward standardization of methods for measuring hemoglobin A1c. Clin Chem. 43:1811–1813, 1997.

9. Groche D, Hoeno W, Hoss G, Vogt B, Herrmann Z, Witzig mann A: Standardization of two immunological HbA1c routine assays according to the new IFCC reference method. Clin Lab. 49:657-661, 2003.
10. Miedema K: Standardization of HbA1c and optimal range of monitoring. Scand J Clin Lab Invest Suppl. 240:61-72, 2005.
11. Weykamp CW, Penders TJ, Muskiet FAJ, van der Slik W: Influence of hemoglobin variants and derivatives on glycohemoglobin determinations, as investigated by 102 laboratories using 16 methods. Clin Chem. 39:1717– 1723, 1993.
12. Bary L, Chen PC, Sacks DB: Effects of hemoglobin variants and chemically modified derivatives on assays for glycohemoglobin. Clin Chem. 47:153-163, 2001.
13. Fraser CG: Biological variation: from principles to practice. Washington: AACC Press. 151 pp, 2001.
14. Sacks DB, Bruns DE, Goldstein DE, Maclaren NK, McDonald JM, Parrott M: Guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus. Clin Chem. 48:436–472, 2002.